Akanda Appoints Christopher Cooper as New CEO; Interim CEO Katie Field Resigns
AKAN sits 45% above its 52-week low of $2.295 on light trading volume (0.2× avg).
Summary
Akanda Corp. announced a leadership transition, with Interim CEO Katie Field resigning and Christopher Cooper, an existing director and subsidiary president, taking over as the new CEO.
Key Events · Executive and Board Changes · AKAN
-
Interim CEO Resignation
Katie Field resigned from all positions as Interim CEO and Executive Director, effective September 3, 2026. The company stated the resignation was not due to any disagreement.
-
New CEO Appointment
Christopher Cooper, an existing director and President of the First Towers and Fiber Corp. subsidiary, was appointed as the new Chief Executive Officer, effective September 3, 2026.
-
Consulting Agreement with Former CEO's Affiliate
Subsequent to her resignation, an affiliate of Ms. Field entered into a month-to-month consulting agreement with the company to provide administrative, consulting, and advisory services.
-
New CEO's Background
Mr. Cooper has over 20 years of business experience in corporate development, senior management, finance, and operations, and serves as a director for multiple public companies.
Analysis · AKAN · Life Sciences
Akanda Corp. has appointed Christopher Cooper, an existing director and President of its First Towers and Fiber Corp. subsidiary, as the new Chief Executive Officer. This leadership change comes as the company navigates Nasdaq compliance issues, having recently received an extension to meet minimum stockholders' equity requirements. The outgoing Interim CEO, Katie Field, resigned but her affiliate will continue to provide consulting services. Cooper's extensive experience and his existing role in the First Towers subsidiary, which has recently reported positive operational news, could provide stability and strategic direction during this critical period for the micro-cap company.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 30% of the 1972 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKAN was trading at $3.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $2.30 to $209.03. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.